Geode Capital Management’s Poseida Therapeutics PSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-1,629,759
Closed -$15.6M – 4565
2024
Q4
$15.6M Buy
1,629,759
+12,622
+0.8% +$65.9K ﹤0.01% 2091
2024
Q3
$4.63M Sell
1,617,137
-5,438
-0.3% -$16.8K ﹤0.01% 2797
2024
Q2
$4.74M Buy
1,622,575
+59,215
+4% +$162K ﹤0.01% 2758
2024
Q1
$4.99M Buy
1,563,360
+40,305
+3% +$134K ﹤0.01% 2707
2023
Q4
$5.12M Buy
1,523,055
+104,738
+7% +$270K ﹤0.01% 2695
2023
Q3
$3.38M Buy
1,418,317
+193,750
+16% +$406K ﹤0.01% 2843
2023
Q2
$2.16M Buy
1,224,567
+718,477
+142% +$1.84M ﹤0.01% 3087
2023
Q1
$1.56M Buy
506,090
+14,618
+3% +$87.6K ﹤0.01% 3137
2022
Q4
$2.6M Buy
491,472
+36,420
+8% +$166K ﹤0.01% 2941
2022
Q3
$1.61M Buy
455,052
+192,571
+73% +$637K ﹤0.01% 3160
2022
Q2
$677K Sell
262,481
-240,551
-48% -$669K ﹤0.01% 3594
2022
Q1
$2.25M Buy
503,032
+12,433
+3% +$56.1K ﹤0.01% 3205
2021
Q4
$3.34M Buy
490,599
+113,850
+30% +$776K ﹤0.01% 3114
2021
Q3
$2.75M Buy
376,749
+205
+0.1% +$1.76K ﹤0.01% 3220
2021
Q2
$3.77M Sell
376,544
-26,249
-7% -$235K ﹤0.01% 3064
2021
Q1
$3.85M Buy
402,793
+189,886
+89% +$1.86M ﹤0.01% 2911
2020
Q4
$2.34M Buy
212,907
+24,067
+13% +$254K ﹤0.01% 3000
2020
Q3
$1.68M Buy
+188,840
New +$2.15M ﹤0.01% 2965

Other funds holding PSTX

Geode Capital Management's PSTX Position: Q1 2025 in Review

Geode Capital Management sold out of Poseida Therapeutics (PSTX) in Q1 2025, closing a stake of 1,629,759 shares — an estimated $15.6M sold.

Geode Capital Management first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $15.6M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Geode Capital Management reported no remaining Poseida Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 1,629,759 Poseida Therapeutics shares in Q1 2025, an estimated $15.6M.
  • Geode Capital Management first reported a position in Poseida Therapeutics in Q3 2020 and held it in 18 quarters.
  • Geode Capital Management's Poseida Therapeutics position peaked at $15.6M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.